These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 38684588)

  • 1. Survey of Data Package and Sample Size of Comparative Clinical Studies for Biosimilar Developments from PMDA Assessments.
    Kuribayashi R; Hariu A; Nakano A; Kishioka Y
    Pharmaceut Med; 2024 May; 38(3):225-239. PubMed ID: 38684588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisions to the requirement of the Japanese clinical study data for biosimilar developments in Japan.
    Kuribayashi R; Goto K; Hariu A; Kishioka Y
    Expert Opin Biol Ther; 2024 Jul; 24(7):637-645. PubMed ID: 38970459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials for authorized biosimilars in the European Union: a systematic review.
    Mielke J; Jilma B; Koenig F; Jones B
    Br J Clin Pharmacol; 2016 Dec; 82(6):1444-1457. PubMed ID: 27580073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009-2022.
    Kuribayashi R; Nakano A; Hariu A; Kishioka Y; Honda F
    BioDrugs; 2023 Jul; 37(4):443-451. PubMed ID: 37227657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.
    Stebbing J; Mainwaring PN; Curigliano G; Pegram M; Latymer M; Bair AH; Rugo HS
    J Clin Oncol; 2020 Apr; 38(10):1070-1080. PubMed ID: 32058846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic Biomarkers Evidentiary Considerations for Biosimilar Development and Approval.
    Strauss DG; Wang YM; Florian J; Zineh I
    Clin Pharmacol Ther; 2023 Jan; 113(1):55-61. PubMed ID: 36178447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.
    Tieu C; Lucas EJ; DePaola M; Rosman L; Alexander GC
    PLoS One; 2018; 13(4):e0195012. PubMed ID: 29668697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of the EU Biosimilar Framework: Past and Future.
    Wolff-Holz E; Tiitso K; Vleminckx C; Weise M
    BioDrugs; 2019 Dec; 33(6):621-634. PubMed ID: 31541400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on the clinical evidence that supports biosimilar approvals in Europe.
    Mielke J; Jilma B; Jones B; Koenig F
    Br J Clin Pharmacol; 2018 Jul; 84(7):1415-1431. PubMed ID: 29575017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Japanese regulation of biosimilar products: past experience and current challenges.
    Arato T
    Br J Clin Pharmacol; 2016 Jul; 82(1):30-40. PubMed ID: 26987746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?
    Kirsch-Stefan N; Guillen E; Ekman N; Barry S; Knippel V; Killalea S; Weise M; Wolff-Holz E
    BioDrugs; 2023 Nov; 37(6):855-871. PubMed ID: 37831324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?
    Tu CL; Wang YL; Hu TM; Hsu LF
    BioDrugs; 2019 Aug; 33(4):437-446. PubMed ID: 31111423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar.
    Gaylis N; Both C; Lemke L; von Richter O; Yamauchi P
    Adv Ther; 2024 May; 41(5):1795-1814. PubMed ID: 38514505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing clinical trials for biosimilars.
    Bui LA; Taylor C
    Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Japanese Regulatory Systems for Generics and Biosimilars.
    Kuribayashi R; Sawanobori K
    J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic Biomarkers for Biosimilar Development and Approval: A Workshop Summary.
    Florian J; Sun Q; Schrieber SJ; White R; Shubow S; Johnson-Williams BE; Sheikhy M; Harrison NR; Parker VJ; Wang YM; Strauss DG
    Clin Pharmacol Ther; 2023 May; 113(5):1030-1035. PubMed ID: 36380593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer.
    Taïeb J; Aranda E; Raouf S; Dunn H; Arnold D
    Clin Colorectal Cancer; 2021 Mar; 20(1):42-51.e3. PubMed ID: 33243618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial development for biosimilars.
    Alten R; Cronstein BN
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S2-8. PubMed ID: 26058550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of PD Biomarkers in Biosimilar Development - To Get the Right Answer One Must First Ask the Right Question.
    Woollett GR; Park JP; Han J; Jung B
    Clin Pharmacol Ther; 2023 Jan; 113(1):50-54. PubMed ID: 36148870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.